{"analyses":[{"ciLowerLimit":"-7.8","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.1","groupDescription":"Primary endpoint was to be assessed at 6-Months: Assuming a 45% MaHR rate in the 70 mg BID participants, the primary efficacy analysis required a total of 540 participants, approximately 270 in each dosing schedule, giving at least 80% power to deduce non-inferiority of the QD schedule relative to the BID schedule if the lower bound of the 95% CI for the difference in MaHR rates (MaHRRQD - MaHRRBID) is greater than -12%.","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of the QD schedule relative to the BID schedule was claimed if the lower bound of the 95% CI for difference (QD - BD) was ≥ -12%.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","paramType":"Percent Difference","paramValue":"0.2","testedNonInferiority":true}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.3","upperLimit":"53.8","value":"48.0"},{"groupId":"OG001","lowerLimit":"42.1","upperLimit":"53.6","value":"47.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"MaHR defined by either complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR defined as: white blood cells (WBC) ≤ upper limit of normal (ULN); absolute neutrophil count (ANC) ≥ 1,000/mm\\^3; platelets ≥ 100,000/mm\\^3; no blasts or promyelocytes in peripheral blood (PB); bone marrow (BM) blasts ≤ 5%; \\<5% myelocytes plus metamyelocytes in PB; basophils in PB \\< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets ≥ 20,000/mm\\^3 and \\< 100,000/mm\\^3; ANC \\> 500/mm\\^3 and \\<1,000/mm\\^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule. Percentage: number of participants with MaHR/number of randomized participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant..","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"Participants were analyzed based on the treatment they were randomized to receive (not what they actually received). 95% exact confidence interval (CI) presented.","reportingStatus":"POSTED","timeFrame":"Randomization up to 6 months","title":"Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population","type":"PRIMARY","unitOfMeasure":"percentage of participants"}